Skip to main content

Table 5 Complications in vaccinated mumps patients by time from the second dose, Czech Republic, 2007–2012

From: Protective effect of vaccination against mumps complications, Czech Republic, 2007–2012

Time from the second dose

MUMPS

COMPLICATIONS

COMPLICATIONS

Adjustedb odds ratio

95 % CI

p value

in years

number of cases

number of cases

% of mumps cases with complications

   

0–1.9

106

1

0.94

Refa

  

2–3.9

287

1

0.35

4–5.9

435

4

0.92

6–7.9

650

11

1.69

2.49

0.91, 6.79

0.074

8–9.9

652

10

1.53

2.21

0.79, 6.13

0.126

10–11.9

865

27

3.12

4.70

1.92, 11.47

0.001

12–13.9

1268

79

6.23

10.3

4.33, 23.21

<0.001

14–15.9

1584

128

8.08

13.59

5.93, 31.13

<0.001

16–17.9

1129

136

12.05

21.28

9.29, 48.76

<0.001

18–19.9

447

52

11.63

20.14

8.53, 47.55

<0.001

20–21.9

240

31

12.92

22.97

9.40, 56.11

<0.001

22–23.9

144

21

14.58

26.70

10.51, 67.87

<0.001

24 and later

43

7

16.28

30.41

9.67, 95.59

<0.001

Total

7850

508

6.47

   
  1. Note
  2. areference category 0–5.9 compounded from three categories: 0–1.9, 2–3.9, 4–5.9 years
  3. bodds ratio adjusted for age at the 2nd dose